Healthcare -
Biotechnology - NASDAQ - US
$ 1.28
1.59 %
$ 76.9 M
Market Cap
-0.93
P/E
1. INTRINSIC VALUE
Balance Sheet
Acumen Pharmaceuticals, Inc.
| Current Assets | 247 M |
| Cash & Short-Term Investments | 244 M |
| Receivables | 225 K |
| Other Current Assets | 2.87 M |
| Non-Current Assets | 63.5 M |
| Long-Term Investments | 62.6 M |
| PP&E | 503 K |
| Other Non-Current Assets | 454 K |
| Current Liabilities | 13 M |
| Accounts Payable | 1.38 M |
| Short-Term Debt | 1.73 M |
| Other Current Liabilities | 9.86 M |
| Non-Current Liabilities | 30.2 M |
| Long-Term Debt | 27.6 M |
| Other Non-Current Liabilities | 2.56 M |
EFFICIENCY
Earnings Waterfall
Acumen Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 184 K |
| Gross Profit | -42.3 M |
| Operating Expenses | 61.1 M |
| Operating Income | -61.1 M |
| Other Expenses | -8.77 M |
| Net Income | -52.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Acumen Pharmaceuticals, Inc.
| Net Income | -52.4 M |
| Depreciation & Amortization | 184 K |
| Capital Expenditures | -21 K |
| Stock-Based Compensation | 6.14 M |
| Change in Working Capital | 3.87 M |
| Others | 3.24 M |
| Free Cash Flow | -43.1 M |
Wall Street Analysts Price Targets
Acumen Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for ABOS of $7 , with forecasts ranging from
a
low of
$7 to a high of $7 .
ABOS Lowest Price Target
Wall Street Target
7 USD
446.88%
ABOS Average Price Target
Wall Street Target
7 USD
446.88%
ABOS Highest Price Target
Wall Street Target
7 USD
446.88%
4. DIVIDEND
ANALYSIS
ABOS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Acumen Pharmaceuticals, Inc.
Sold
0-3 MONTHS
259 K USD 5
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 month ago
Jan 21, 2025
|
Sell 6.99 K
USD
|
Zuga Matt
CFO & Chief Business Officer
|
- 4364
|
1.6009 USD |
|
1 month ago
Jan 23, 2025
|
Sell 49.6 K
USD
|
Zuga Matt
CFO & Chief Business Officer
|
- 28902
|
1.7173 USD |
|
1 month ago
Jan 21, 2025
|
Sell 20.1 K
USD
|
OConnell Daniel Joseph
Chief Executive Officer
|
- 12619
|
1.593 USD |
|
1 month ago
Jan 21, 2025
|
Sell 5.43 K
USD
|
Meisner Derek M
Chief Legal Officer & Corp Sec
|
- 3418
|
1.59 USD |
|
1 month ago
Jan 21, 2025
|
Sell 4.69 K
USD
|
Barton Russell
Chief Operating Officer
|
- 2914
|
1.6102 USD |
|
1 month ago
Jan 21, 2025
|
Sell 5.12 K
USD
|
Siemers Eric
Chief Medical Officer
|
- 3219
|
1.59 USD |
|
1 month ago
Jan 03, 2025
|
Sell 87.9 K
USD
|
OConnell Daniel Joseph
Chief Executive Officer
|
- 47778
|
1.8392 USD |
|
1 month ago
Jan 03, 2025
|
Sell 20.5 K
USD
|
Meisner Derek M
Chief Legal Officer & Corp Sec
|
- 11122
|
1.8437 USD |
|
1 month ago
Jan 03, 2025
|
Sell 14.2 K
USD
|
Barton Russell
Chief Operating Officer
|
- 7636
|
1.8629 USD |
|
1 month ago
Jan 03, 2025
|
Sell 24.4 K
USD
|
Zuga Matt
CFO & Chief Business Officer
|
- 13235
|
1.8411 USD |
|
1 month ago
Jan 03, 2025
|
Sell 20 K
USD
|
Siemers Eric
Chief Medical Officer
|
- 10859
|
1.8461 USD |
|
1 year ago
Jan 19, 2024
|
Sell 52.8 K
USD
|
OConnell Daniel Joseph
President and CEO
|
- 15200
|
3.4706 USD |
|
1 year ago
Jan 19, 2024
|
Sell 31 K
USD
|
Meisner Derek M
Chief Legal Officer & Corp Sec
|
- 8933
|
3.4757 USD |
|
1 year ago
Jan 18, 2024
|
Sell 15.7 K
USD
|
Zuga Matt
CFO & Chief Business Officer
|
- 4242
|
3.705 USD |
|
1 year ago
Jan 18, 2024
|
Sell 11.6 K
USD
|
Siemers Eric
Chief Medical Officer
|
- 3124
|
3.7144 USD |
|
1 year ago
Jan 18, 2024
|
Sell 10.6 K
USD
|
Barton Russell
Chief Operating Officer
|
- 2833
|
3.7258 USD |
|
1 year ago
Aug 17, 2023
|
Sell 254 K
USD
|
Ives Jeffrey L.
Director
|
- 39149
|
6.48 USD |
|
1 year ago
Aug 17, 2023
|
Sell 18.6 K
USD
|
Ives Jeffrey L.
Director
|
- 2800
|
6.66 USD |
|
1 year ago
Jul 21, 2023
|
Bought
40 M USD
|
RA CAPITAL MANAGEMENT, L.P.
director, 10 percent owner:
|
+ 5161290
|
7.75 USD |
|
3 years ago
Jul 06, 2021
|
Bought
5 M USD
|
Manning Paul B
10 percent owner
|
+ 312500
|
16 USD |
|
3 years ago
Jul 06, 2021
|
Bought
560 K USD
|
Stalfort John A III
Director
|
+ 35000
|
16 USD |
|
3 years ago
Jul 06, 2021
|
Bought
5 M USD
|
Hardie Robert D.
10 percent owner
|
+ 312500
|
16 USD |
|
3 years ago
Jul 06, 2021
|
Bought
12 M USD
|
Hardie Robert D.
10 percent owner
|
+ 750000
|
16 USD |
|
3 years ago
Jul 06, 2021
|
Bought
100 K USD
|
Fountain Nathan B
Director
|
+ 6250
|
16 USD |
|
3 years ago
Jul 06, 2021
|
Bought
6.7 M USD
|
Sands Capital Ventures Discovery Fund III, L.P.
10 percent owner
|
+ 450000
|
14.88 USD |
|
3 years ago
Jul 06, 2021
|
Bought
28.1 M USD
|
RA CAPITAL MANAGEMENT, L.P.
director, 10 percent owner:
|
+ 1759332
|
16 USD |
|
3 years ago
Jul 06, 2021
|
Bought
1.85 M USD
|
RA CAPITAL MANAGEMENT, L.P.
director, 10 percent owner:
|
+ 115668
|
16 USD |
|
18 years ago
Sep 15, 2006
|
Bought
700 USD
|
STOVER JACK E
Director
|
+ 1000
|
0.7 USD |
|
18 years ago
Jun 12, 2006
|
Bought
11.2 K USD
|
Kogod Dennis
Director
|
+ 10000
|
1.12 USD |
7. News
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
globenewswire.com
- 3 months ago
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2024 Results Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Braun - Head of Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer, Chief Business Officer Dr. Jim Doherty - President, Chief Development Officer Dr. Eric Siemers - Chief Medical Officer. Conference Call Participants Mark Hitrik - Stifel Tom Shrader - BTIG Cameron Bozdog - BofA Securities Samantha Schaeffer - Cantor Fitzgerald Operator Hello, and welcome to Acumen Pharmaceuticals Q3 2024 Conference Call and Webcast.
seekingalpha.com
- 3 months ago
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET.
globenewswire.com
- 3 months ago
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, Nov. 13, 2024, at 1:15 p.m. PT (4:15 p.m. ET).
globenewswire.com
- 3 months ago
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference
NEWTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today presented updated data on a validated research-use plasma pTau217 assay to screen potential participants in the ongoing Phase 2 ALTITUDE-AD clinical trial of sabirnetug, at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference. The study found that this enrichment screening approach is resulting in a higher proportion of participants who meet the amyloid PET or CSF-based inclusion criteria compared to Acumen's Phase 1 INTERCEPT-AD trial, which did not use this approach. Furthermore, the enrichment approach is resulting in a more efficient participant selection process that reduces unnecessary amyloid PET scans or lumbar puncture (LP) procedures among people who are not eligible to continue in screening.
globenewswire.com
- 4 months ago
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
- Presentation to focus on use of validated pTau217 assay in participant screening process for Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer's disease
globenewswire.com
- 4 months ago
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Bank of America CNS Therapeutics Virtual Conference on Monday, Oct. 7, 2024, at 8:00 a.m. ET.
globenewswire.com
- 5 months ago
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the Company will host a virtual R&D Day on Wednesday, Oct. 2 at 10:00 a.m. ET. The webcast will highlight Acumen's strategic vision, and focus on the mechanistic rationale, pre-clinical and clinical data that support further development of sabirnetug as a treatment for early AD.
globenewswire.com
- 5 months ago
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
NEWTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investor Conference on Tuesday, Sept. 10, 2024, at 1:30 p.m. ET.
globenewswire.com
- 5 months ago
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer, Chief Business Officer Dr. Jim Doherty - President, Chief Development Officer Dr. Eric Siemers - Chief Medical Officer. Alex Braun - Head of Investor Relations Conference Call Participants Tom Shrader - BTIG Cameron Bozdog - Bank of America Samantha Schaeffer - Cantor Fitzgerald Trung Huynh - UBS Ananda Ghosh - HC Wainwright Operator Hello, and thank you for standing by.
seekingalpha.com
- 6 months ago
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
NEWTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report second quarter 2024 financial results on Tuesday, August 13, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
globenewswire.com
- 6 months ago
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Acumen Pharmaceuticals develops treatments for Alzheimer's disease targeting toxic AβOs, with promising results for sabirnetug in phase 1 clinical trial Intercept-AD. The potential for early AD is approximately 7 million patients, positioning ABOS for significant market share if successful. Sabirnetug's Phase 1 trial showed promising results, reducing brain amyloid plaques and supporting its mechanism of action for treating early Alzheimer's disease.
seekingalpha.com
- 7 months ago
8. Profile
Summary
Acumen Pharmaceuticals, Inc. ABOS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 76.9 M
Dividend Yield
0.00%
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Contact
427 Park Street, Charlottesville, VA, 22902
https://acumenpharm.com
IPO
Date
July 1, 2021
Employees
51
Officers
Ms. Alex Braun M.B.A.
Vice President & Head of Investor Relations
Mr. Matt Zuga
Chief Financial Officer & Chief Business Officer
Dr. James Doherty Ph.D.
President & Chief Development Officer
Dr. Caleb E. Finch Ph.D.
Co-Founder
Mr. Russell Barton M.S.
Chief Operating Officer
Mr. Daniel J. O'Connell M.B.A.
Chief Executive Officer & Director
Mr. Derek M. Meisner Esq., J.D.
Chief Legal Officer & Corporate Secretary
Dr. Grant A. Krafft Ph.D.
Co-Founder
Dr. William L. Klein Ph.D.
Co-Founder
Ms. Kelly Carranza
Vice President, Finance & Accounting and Corporate Controller